Immunoregulatory effects on T lymphocytes by human mesenchymal stromal cells isolated from bone marrow, amniotic fluid, and placenta.

[1]  A. Fierabracci,et al.  How far are we from the clinical use of placental-derived mesenchymal stem cells? , 2015, Expert opinion on biological therapy.

[2]  Imran Ullah,et al.  Human mesenchymal stem cells - current trends and future prospective , 2015, Bioscience reports.

[3]  B. Hahn,et al.  Th17 cells in inflammation and autoimmunity. , 2014, Autoimmunity reviews.

[4]  M. Pozzobon,et al.  CD117+ amniotic fluid stem cells vary their immune regulatory properties according to gestational age , 2014 .

[5]  L. Labanca,et al.  Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions , 2014, Cytotherapy.

[6]  Wenwen Jia,et al.  Human amniotic fluid stem cells suppress PBMC proliferation through IDO and IL-10-dependent pathways. , 2013, Current stem cell research & therapy.

[7]  F. Fagioli,et al.  Validation of analytical methods in compliance with good manufacturing practice: a practical approach , 2013, Journal of Translational Medicine.

[8]  F. Djouad,et al.  Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells , 2013, Stem Cell Research & Therapy.

[9]  F. Dazzi,et al.  Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance? , 2013, Immunology and cell biology.

[10]  S. Shi,et al.  A subset of IL-17+ mesenchymal stem cells possesses anti-Candida albicans effect , 2012, Cell Research.

[11]  H. Jeon,et al.  Placenta-Derived Mesenchymal Stem Cells Have an Immunomodulatory Effect That Can Control Acute Graft-Versus-Host Disease in Mice , 2012, Acta Haematologica.

[12]  Jung Min Lee,et al.  Comparison of immunomodulatory effects of placenta mesenchymal stem cells with bone marrow and adipose mesenchymal stem cells. , 2012, International immunopharmacology.

[13]  T. Cai,et al.  Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. , 2012, Cell stem cell.

[14]  C. V. van Blitterswijk,et al.  Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. , 2012, Tissue engineering. Part B, Reviews.

[15]  R. Lechler,et al.  Placenta‐derived MSCs are partially immunogenic and less immunomodulatory than bone marrow‐derived MSCs , 2011, Journal of tissue engineering and regenerative medicine.

[16]  H. Koistinen,et al.  Differential actions of glycodelin-A on Th-1 and Th-2 cells: a paracrine mechanism that could produce the Th-2 dominant environment during pregnancy. , 2011, Human reproduction.

[17]  A. Cometa,et al.  Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation , 2011, Bone Marrow Transplantation.

[18]  Shilpa Shankar,et al.  Pro-Inflammatory Cytokines, IFNγ and TNFα, Influence Immune Properties of Human Bone Marrow and Wharton Jelly Mesenchymal Stem Cells Differentially , 2010, PloS one.

[19]  Zhenping Chen,et al.  Fetal BM‐derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells , 2009, European journal of immunology.

[20]  B. Sun,et al.  Reciprocal effect of mesenchymal stem cell on experimental autoimmune encephalomyelitis is mediated by transforming growth factor‐β and interleukin‐6 , 2009, Clinical and experimental immunology.

[21]  E. Medico,et al.  Multipotent mesenchymal stem cells from amniotic fluid originate neural precursors with functional voltage-gated sodium channels. , 2009, Cytotherapy.

[22]  S. Miller,et al.  Human bone marrow‐derived mesenchymal stem cells induce Th2‐polarized immune response and promote endogenous repair in animal models of multiple sclerosis , 2009, Glia.

[23]  L. Miteva,et al.  The influence of JNK and P38 MAPK inhibition on IL-12P40 and IL-23 production depending on IL12B promoter polymorphism , 2009, Cellular & Molecular Biology Letters.

[24]  M. Delgado,et al.  Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. , 2009, Tissue engineering. Part A.

[25]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[26]  F. Montecucco,et al.  Human Mesenchymal Stem Cells Inhibit Neutrophil Apoptosis: A Model for Neutrophil Preservation in the Bone Marrow Niche , 2008, Stem cells.

[27]  L. Cosmi,et al.  Toll‐Like Receptors 3 and 4 Are Expressed by Human Bone Marrow‐Derived Mesenchymal Stem Cells and Can Inhibit Their T‐Cell Modulatory Activity by Impairing Notch Signaling , 2008, Stem cells.

[28]  A. Vercelli,et al.  Neural differentiation of human mesenchymal stem cells: Evidence for expression of neural markers and eag K+ channel types. , 2006, Experimental hematology.

[29]  Franca Fagioli,et al.  Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow , 2006, Journal of cellular biochemistry.

[30]  W. Paul,et al.  IL-6 Increases Primed Cell Expansion and Survival , 2005, The Journal of Immunology.

[31]  D. Mevorach,et al.  Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. , 2005, Blood.

[32]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[33]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[34]  O. Ringdén,et al.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. , 2003, Experimental hematology.

[35]  G. Sukhikh,et al.  Mesenchymal Stem Cells , 2002, Bulletin of Experimental Biology and Medicine.

[36]  M. Mattson,et al.  Stem cells and aging: expanding the possibilities , 2001, Mechanisms of Ageing and Development.

[37]  M. Sarih,et al.  Different cytokine profiles of peripheral blood mononuclear cells from patients with persistent and self-limited hepatitis C virus infection. , 2000, Immunology letters.

[38]  J. Fahey,et al.  Cytokine Gene Expression in Normal Human Lymphocytes in Response to Stimulation , 1998, Clinical Diagnostic Laboratory Immunology.

[39]  P. Marrack,et al.  IL-6 rescues resting mouse T cells from apoptosis. , 1997, Journal of immunology.

[40]  M. Pozzobon,et al.  Immune regulatory properties of CD117(pos) amniotic fluid stem cells vary according to gestational age. , 2015, Stem cells and development.

[41]  Fagioli Franca,et al.  COMPARING THE IMMUNOREGULATORY EFFECTS OF MESENCHYMAL STEM CELLS ISOALTED FROM BONE MARROW, PLACENTA AND AMNIOTIC FLUID , 2014 .

[42]  P. Martiat,et al.  Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. , 2009, Cytotherapy.

[43]  D. Roelen,et al.  Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells. , 2009, Human immunology.

[44]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[45]  A. Cometa,et al.  Inherited thrombocytopenias: from genes to therapy , 1994 .

[46]  O. Ringdén,et al.  Immunologic properties of human fetal mesenchymal stem cells. , 2004, American journal of obstetrics and gynecology.